Trial Profile

A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Plasma Pharmacokinetics and Safety of Obicetrapib in Participants With Moderate Hepatic Impairment Relative to Participants With Normal Hepatic Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obicetrapib (Primary)
Indications Alzheimer's disease; Dyslipidaemias; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
Focus Pharmacokinetics
Sponsors NewAmsterdam Pharma

19 Sep 2024 Status changed from recruiting to completed.
20 Jan 2024 Planned End Date changed from 30 May 2024 to 30 Jul 2024.
20 Jan 2024 Planned primary completion date changed from 30 Apr 2024 to 31 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com